Hormone Receptor Expression Varies by Molecular Subtype, Age, and Sex in Pheochromocytoma and Paraganglioma: A Transcriptomic Analysis

Purpose The role of hormone receptor (HR) signaling in pheochromocytoma and paraganglioma (PCPG) is incompletely defined. We characterized HR expression across PCPG molecular subtypes and its clinicopathologic, transcriptional, and outcome associations. Methods RNA-sequencing data from 151 primary tumors (one per patient) in The Cancer Genome Atlas were analyzed for ESR1, ESR2, GPER1, PGR, AR, LHCGR, and the glucocorticoid receptor gene NR3C1. Expression was compared by molecular cluster (pseudohypoxia, kinase signaling, Wnt-altered), age, sex, and metastatic status using non-parametric tests. Event-free survival (EFS) was assessed with Cox models, and ESR1- and AR-associated programs with gene set enrichment analysis. Cluster patterns were tested in the independent E-MTAB-733 cohort. Results Pseudohypoxia tumors had higher ESR1 and PGR and lower LHCGR expression than other clusters (all p < 0.001), a pattern seen in both sexes. Kinase-signaling tumors had lower GPER1 and AR expression. NR3C1 did not differ by cluster. ESR1 and PGR decreased and LHCGR increased with age, predominantly in male patients. Lower LHCGR in pseudohypoxia tumors and lower AR in kinase-signaling tumors were associated with metastatic disease. No receptor was associated with EFS; overall survival could not be modeled (five deaths). In pseudohypoxia tumors, ESR1-high cases showed immune-enriched programs and AR-high cases developmental programs with oxidative phosphorylation depletion. Externally, cluster differences in PGR, LHCGR, AR, and GPER1, but not ESR1, were reproduced. Conclusion HR expression in PCPG varies by molecular subtype, age, and sex, and selected receptors track with metastatic behavior and distinct transcriptional programs. Protein-level validation and larger outcome-annotated cohorts are needed.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11393304/v1
Primary Topic
Adrenal and Paraganglionic Tumors
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Hormone Receptor Expression Varies by Molecular Subtype, Age, and Sex in Pheochromocytoma and Paraganglioma: A Transcriptomic Analysis

Naris Nilubol, Rachyl M. Shanker, Lindsay F. Remer, Genevieve F. Gilson
Research Square
Adrenal and Paraganglionic Tumors
preprint

Hormone Receptor Expression Varies by Molecular Subtype, Age, and Sex in Pheochromocytoma and Paraganglioma: A Transcriptomic Analysis

Naris Nilubol, Rachyl M. Shanker, Lindsay F. Remer, Genevieve F. Gilson
preprint en

Abstract

Purpose The role of hormone receptor (HR) signaling in pheochromocytoma and paraganglioma (PCPG) is incompletely defined. We characterized HR expression across PCPG molecular subtypes and its clinicopathologic, transcriptional, and outcome associations. Methods RNA-sequencing data from 151 primary tumors (one per patient) in The Cancer Genome Atlas were analyzed for ESR1, ESR2, GPER1, PGR, AR, LHCGR, and the glucocorticoid receptor gene NR3C1. Expression was compared by molecular cluster (pseudohypoxia, kinase signaling, Wnt-altered), age, sex, and metastatic status using non-parametric tests. Event-free survival (EFS) was assessed with Cox models, and ESR1- and AR-associated programs with gene set enrichment analysis. Cluster patterns were tested in the independent E-MTAB-733 cohort. Results Pseudohypoxia tumors had higher ESR1 and PGR and lower LHCGR expression than other clusters (all p < 0.001), a pattern seen in both sexes. Kinase-signaling tumors had lower GPER1 and AR expression. NR3C1 did not differ by cluster. ESR1 and PGR decreased and LHCGR increased with age, predominantly in male patients. Lower LHCGR in pseudohypoxia tumors and lower AR in kinase-signaling tumors were associated with metastatic disease. No receptor was associated with EFS; overall survival could not be modeled (five deaths). In pseudohypoxia tumors, ESR1-high cases showed immune-enriched programs and AR-high cases developmental programs with oxidative phosphorylation depletion. Externally, cluster differences in PGR, LHCGR, AR, and GPER1, but not ESR1, were reproduced. Conclusion HR expression in PCPG varies by molecular subtype, age, and sex, and selected receptors track with metastatic behavior and distinct transcriptional programs. Protein-level validation and larger outcome-annotated cohorts are needed.

Research Square
National Cancer Institute (US)
Adrenal and Paraganglionic Tumors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon